Recent Progress toward Microfluidic Quality Control Testing of Radiopharmaceuticals

Radiopharmaceuticals labeled with short-lived positron-emitting or gamma-emitting isotopes are injected into patients just prior to performing positron emission tomography (PET) or single photon emission tomography (SPECT) scans, respectively. These imaging modalities are widely used in clinical car...

Full description

Bibliographic Details
Main Authors: Noel S. Ha, Saman Sadeghi, R. Michael van Dam
Format: Article
Language:English
Published: MDPI AG 2017-11-01
Series:Micromachines
Subjects:
Online Access:https://www.mdpi.com/2072-666X/8/11/337
id doaj-091b8bd998cd41ee92ff8f4990043fad
record_format Article
spelling doaj-091b8bd998cd41ee92ff8f4990043fad2020-11-25T00:21:26ZengMDPI AGMicromachines2072-666X2017-11-0181133710.3390/mi8110337mi8110337Recent Progress toward Microfluidic Quality Control Testing of RadiopharmaceuticalsNoel S. Ha0Saman Sadeghi1R. Michael van Dam2Department of Bioengineering, Henry Samueli School of Engineering and Applied Science, University of California Los Angeles, Los Angeles, CA 90095, USACrump Institute for Molecular Imaging and Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USADepartment of Bioengineering, Henry Samueli School of Engineering and Applied Science, University of California Los Angeles, Los Angeles, CA 90095, USARadiopharmaceuticals labeled with short-lived positron-emitting or gamma-emitting isotopes are injected into patients just prior to performing positron emission tomography (PET) or single photon emission tomography (SPECT) scans, respectively. These imaging modalities are widely used in clinical care, as well as in the development and evaluation of new therapies in clinical research. Prior to injection, these radiopharmaceuticals (tracers) must undergo quality control (QC) testing to ensure product purity, identity, and safety for human use. Quality tests can be broadly categorized as (i) pharmaceutical tests, needed to ensure molecular identity, physiological compatibility and that no microbiological, pyrogenic, chemical, or particulate contamination is present in the final preparation; and (ii) radioactive tests, needed to ensure proper dosing and that there are no radiochemical and radionuclidic impurities that could interfere with the biodistribution or imaging. Performing the required QC tests is cumbersome and time-consuming, and requires an array of expensive analytical chemistry equipment and significant dedicated lab space. Calibrations, day of use tests, and documentation create an additional burden. Furthermore, in contrast to ordinary pharmaceuticals, each batch of short-lived radiopharmaceuticals must be manufactured and tested within a short period of time to avoid significant losses due to radioactive decay. To meet these challenges, several efforts are underway to develop integrated QC testing instruments that automatically perform and document all of the required tests. More recently, microfluidic quality control systems have been gaining increasing attention due to vastly reduced sample and reagent consumption, shorter analysis times, higher detection sensitivity, increased multiplexing, and reduced instrumentation size. In this review, we describe each of the required QC tests and conventional testing methods, followed by a discussion of efforts to directly miniaturize the test or examples in the literature that could be implemented for miniaturized QC testing.https://www.mdpi.com/2072-666X/8/11/337radiopharmaceuticalspharmaceuticalsmicrofluidicsquality control (QC) testingpositron emission tomography (PET)single photon emission computed tomography (SPECT)lab-on-a-chipsensor
collection DOAJ
language English
format Article
sources DOAJ
author Noel S. Ha
Saman Sadeghi
R. Michael van Dam
spellingShingle Noel S. Ha
Saman Sadeghi
R. Michael van Dam
Recent Progress toward Microfluidic Quality Control Testing of Radiopharmaceuticals
Micromachines
radiopharmaceuticals
pharmaceuticals
microfluidics
quality control (QC) testing
positron emission tomography (PET)
single photon emission computed tomography (SPECT)
lab-on-a-chip
sensor
author_facet Noel S. Ha
Saman Sadeghi
R. Michael van Dam
author_sort Noel S. Ha
title Recent Progress toward Microfluidic Quality Control Testing of Radiopharmaceuticals
title_short Recent Progress toward Microfluidic Quality Control Testing of Radiopharmaceuticals
title_full Recent Progress toward Microfluidic Quality Control Testing of Radiopharmaceuticals
title_fullStr Recent Progress toward Microfluidic Quality Control Testing of Radiopharmaceuticals
title_full_unstemmed Recent Progress toward Microfluidic Quality Control Testing of Radiopharmaceuticals
title_sort recent progress toward microfluidic quality control testing of radiopharmaceuticals
publisher MDPI AG
series Micromachines
issn 2072-666X
publishDate 2017-11-01
description Radiopharmaceuticals labeled with short-lived positron-emitting or gamma-emitting isotopes are injected into patients just prior to performing positron emission tomography (PET) or single photon emission tomography (SPECT) scans, respectively. These imaging modalities are widely used in clinical care, as well as in the development and evaluation of new therapies in clinical research. Prior to injection, these radiopharmaceuticals (tracers) must undergo quality control (QC) testing to ensure product purity, identity, and safety for human use. Quality tests can be broadly categorized as (i) pharmaceutical tests, needed to ensure molecular identity, physiological compatibility and that no microbiological, pyrogenic, chemical, or particulate contamination is present in the final preparation; and (ii) radioactive tests, needed to ensure proper dosing and that there are no radiochemical and radionuclidic impurities that could interfere with the biodistribution or imaging. Performing the required QC tests is cumbersome and time-consuming, and requires an array of expensive analytical chemistry equipment and significant dedicated lab space. Calibrations, day of use tests, and documentation create an additional burden. Furthermore, in contrast to ordinary pharmaceuticals, each batch of short-lived radiopharmaceuticals must be manufactured and tested within a short period of time to avoid significant losses due to radioactive decay. To meet these challenges, several efforts are underway to develop integrated QC testing instruments that automatically perform and document all of the required tests. More recently, microfluidic quality control systems have been gaining increasing attention due to vastly reduced sample and reagent consumption, shorter analysis times, higher detection sensitivity, increased multiplexing, and reduced instrumentation size. In this review, we describe each of the required QC tests and conventional testing methods, followed by a discussion of efforts to directly miniaturize the test or examples in the literature that could be implemented for miniaturized QC testing.
topic radiopharmaceuticals
pharmaceuticals
microfluidics
quality control (QC) testing
positron emission tomography (PET)
single photon emission computed tomography (SPECT)
lab-on-a-chip
sensor
url https://www.mdpi.com/2072-666X/8/11/337
work_keys_str_mv AT noelsha recentprogresstowardmicrofluidicqualitycontroltestingofradiopharmaceuticals
AT samansadeghi recentprogresstowardmicrofluidicqualitycontroltestingofradiopharmaceuticals
AT rmichaelvandam recentprogresstowardmicrofluidicqualitycontroltestingofradiopharmaceuticals
_version_ 1725362780091973632